{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:54:22Z","timestamp":1772643262505,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jdcr.2024.09.019","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T02:43:17Z","timestamp":1728614597000},"page":"31-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Treatment of immune checkpoint inhibitor-induced bullous pemphigoid with methotrexate"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1257-0022","authenticated-orcid":false,"given":"Emma L.","family":"Myers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9185-3548","authenticated-orcid":false,"given":"Paul B.","family":"Googe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7692-6446","authenticated-orcid":false,"given":"Donna A.","family":"Culton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jdcr.2024.09.019_bib1","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3740","article-title":"Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a review of the literature","volume":"101","author":"Tsiogka","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"4-5","key":"10.1016\/j.jdcr.2024.09.019_bib2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.autrev.2014.01.047","article-title":"Diagnosis and classification of autoimmune blistering diseases","volume":"13","author":"Baum","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jdcr.2024.09.019_bib3","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2024.09.019_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2021.09.032","article-title":"Methotrexate in the treatment of immune checkpoint blocker-induced bullous pemphigoid","volume":"159","author":"Shi","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.jdcr.2024.09.019_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ced.13042","article-title":"Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression","volume":"42","author":"Rofe","year":"2017","journal-title":"Clin Exp Dermatol"},{"issue":"23","key":"10.1016\/j.jdcr.2024.09.019_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316786","article-title":"From molecular insights to clinical perspectives in drug-associated bullous pemphigoid","volume":"24","author":"de Nicolas-Ruanes","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jdcr.2024.09.019_bib7","first-page":"1126","article-title":"Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and\u00a0idiopathic bullous pemphigoid: a cross-sectional study","volume":"183","author":"Molina","year":"2020","journal-title":"Br\u00a0J\u00a0Dermatol"},{"key":"10.1016\/j.jdcr.2024.09.019_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2024.09.019_bib9","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2019.08.045","article-title":"BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors","volume":"82","author":"Hasan Ali","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2024.09.019_bib10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/bjd\/ljad149","article-title":"Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment","volume":"189","author":"Shipman","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdcr.2024.09.019_bib11","doi-asserted-by":"crossref","first-page":"D327955136","DOI":"10.5070\/D327955136","article-title":"Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature","volume":"27","author":"Klepper","year":"2021","journal-title":"Dermatol Online J"},{"issue":"1","key":"10.1016\/j.jdcr.2024.09.019_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/bjd\/ljad324","article-title":"Targeting interleukin (IL)-4\/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy","volume":"190","author":"Guerrero-Juarez","year":"2023","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jdcr.2024.09.019_bib13","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3390\/cancers14051296","article-title":"Is timing of steroid exposure prior to immune checkpoint inhibitor initiation associated with treatment outcomes in melanoma? A population-based study","volume":"14","author":"Nikita","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jdcr.2024.09.019_bib14","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/archderm.144.5.612","article-title":"A retrospective analysis of patients with bullous pemphigoid treated with methotrexate","volume":"144","author":"Kjellman","year":"2008","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2024.09.019_bib15","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3390\/jcm12041638","article-title":"Can methotrexate be employed as monotherapy for bullous pemphigoid? Analysis of efficiency and tolerance of methotrexate treatment in patients with bullous pemphigoid","volume":"12","author":"Wojtczak","year":"2023","journal-title":"J Clin Med"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624003886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624003886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T08:42:01Z","timestamp":1734424921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512624003886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":15,"alternative-id":["S2352512624003886"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.09.019","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of immune checkpoint inhibitor-induced bullous pemphigoid with methotrexate","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}